BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lv M, Xue G, Cheng H, Meng P, Lian X, Hölscher C, Li D. The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01. Brain Behav 2021;11:e2231. [PMID: 34125470 DOI: 10.1002/brb3.2231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang B, Hu G, Zong X, Yang S, He D, Gao X, Liu D. α-Cyperone protects dopaminergic neurons and inhibits neuroinflammation in LPS-induced Parkinson's disease rat model via activating Nrf2/HO-1 and suppressing NF-κB signaling pathway. Int Immunopharmacol 2023;115:109698. [PMID: 36634417 DOI: 10.1016/j.intimp.2023.109698] [Reference Citation Analysis]
2 Zhang L, Li C, Zhang Z, Zhang Z, Jin Q, Li L, Hölscher C. DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson’s Disease Rat Model. Parkinson's Disease 2022;2022:1-11. [DOI: 10.1155/2022/1428817] [Reference Citation Analysis]
3 Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 2022;239:108277. [DOI: 10.1016/j.pharmthera.2022.108277] [Reference Citation Analysis]
4 Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106550] [Reference Citation Analysis]
5 Reich N, Hölscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front Neurosci 2022;16:970925. [DOI: 10.3389/fnins.2022.970925] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Dong M, Wen S, Zhou L. The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors. Diabetes Metab Syndr Obes 2022;15:2583-97. [PMID: 36035518 DOI: 10.2147/DMSO.S375559] [Reference Citation Analysis]
7 Diz-chaves Y, Mastoor Z, Spuch C, González-matías LC, Mallo F. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. IJMS 2022;23:9583. [DOI: 10.3390/ijms23179583] [Reference Citation Analysis]
8 Haas J, Berg D, Bosy-Westphal A, Schaeffer E. Parkinson's Disease and Sugar Intake-Reasons for and Consequences of a Still Unclear Craving. Nutrients 2022;14:3240. [PMID: 35956417 DOI: 10.3390/nu14153240] [Reference Citation Analysis]
9 Hölscher C. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases. Front Synaptic Neurosci 2022;14:955258. [DOI: 10.3389/fnsyn.2022.955258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease. Expert Opin Ther Targets 2022. [PMID: 35584372 DOI: 10.1080/14728222.2022.2079492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Zhang Z, Li H, Su Y, Ma J, Yuan Y, Yu Z, Shi M, Shao S, Zhang Z, Hölscher C. Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model. Front Neurosci 2022;16:814430. [DOI: 10.3389/fnins.2022.814430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 González LF, Bevilacqua LE, Naves R. Nanotechnology-Based Drug Delivery Strategies to Repair the Mitochondrial Function in Neuroinflammatory and Neurodegenerative Diseases. Pharmaceutics 2021;13:2055. [PMID: 34959337 DOI: 10.3390/pharmaceutics13122055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]